KaloBios Inc. is a biopharmaceutical company that focuses on developing treatments for respiratory diseases and specific types of cancers. Founded in 2000, the company's primary objective is to create advanced therapies for patients suffering from neglected and rare conditions, with a particular emphasis on improving existing marketed antibody products.
Specializing in the biotechnology industry, KaloBios Inc. recently received a Post-IPO Equity investment on 01 July 2020 from Sanofi Ventures. The company's slogan, "Advancing Treatment Solutions for Respiratory Diseases and Rare Cancers," underscores its commitment to developing innovative solutions for challenging medical issues.